Götz Hannelore M, van Bergen Jan E A M, Philips-Santman Cezanne, van Benthem Birgit H B
RIVM-Centrum voor Infectieziektebestrijding, Bilthoven.
Contact: H.M. Götz (
Ned Tijdschr Geneeskd. 2018 May 18;162:D2703.
Effective partner notification and partner treatment are essential to prevent reinfection with Chlamydia trachomatis. For this reason we investigated the possibilities for patient-initiated partner therapy (PIPT) in the Netherlands.
Database research, questionnaires and interviews.
The current practices of partner notification and partner treatment were assessed by means of databases and questionnaires. Facilitators of, and barriers to, the introduction of PIPT were qualitatively explored among professionals at GP practices and sexual health centres. In addition, we interviewed chlamydia patients and their notified partners. Finally, the legal possibilities for PIPT in the Netherlands were explored.
At sexual health centres, regular partners were treated pending test results in 97% of chlamydia cases. Professionals were reluctant to hand out medication to patients for their partners; GPs indicated that they did this in 6% of cases of chlamydia. Patients also saw barriers. The interviewees indicated that the process of partner notification could be improved. Both professionals and patients had a clear preference for combining PIPT with the offer of a (home) test. If those partners notified about chlamydia were not tested, 10% of all gonococcal infections would be missed.
Currently, the widespread introduction of PIPT does not seem to be a good option for the Netherlands. PIPT could be implemented for current regular partners and those who would otherwise not be tested. The combination of a home test kit with PIPT is then preferable. Taking current legislation into account, sexual health centres run by local public health departments are probably the best starting position for PIPT. We recommend that this be further explored.
有效的性伴侣通知和性伴侣治疗对于预防沙眼衣原体再次感染至关重要。因此，我们在荷兰调查了患者发起性伴侣治疗（PIPT）的可能性。
数据库研究、问卷调查和访谈。
通过数据库和问卷调查评估性伴侣通知和性伴侣治疗的当前做法。在全科医生诊所和性健康中心的专业人员中，定性探索了引入PIPT的促进因素和障碍。此外，我们采访了衣原体患者及其被通知的性伴侣。最后，探讨了荷兰PIPT的法律可能性。
在性健康中心，97%的衣原体病例中，其固定性伴侣在检测结果出来之前就接受了治疗。专业人员不愿将药物交给患者让其带给性伴侣；全科医生表示，他们在6%的衣原体病例中会这样做。患者也看到了障碍。受访者表示，性伴侣通知的过程可以改进。专业人员和患者都明确倾向于将PIPT与提供（家庭）检测相结合。如果那些被通知感染衣原体的性伴侣没有接受检测，所有淋球菌感染病例中有10%会被漏诊。
目前，在荷兰广泛引入PIPT似乎不是一个好选择。PIPT可以应用于当前的固定性伴侣以及那些原本不会接受检测的性伴侣。那么将家庭检测试剂盒与PIPT相结合是更可取的。考虑到现行法律，由当地公共卫生部门运营的性健康中心可能是开展PIPT的最佳起点。我们建议对此进行进一步探索。
